文献速递瓣膜病与结构性心脏病

经导管主动脉瓣置换术站点绩效复合指标:STS/ACC TVT注册研究结果

Composite Metric for Benchmarking Site Performance in Transcatheter Aortic Valve Replacement: Results From the STS/ACC TVT Registry.
PubMed 文献 · Circulation · 2021-05-05

复合指标纳入卒中、出血、急性肾损伤和瓣周反流,按严重程度排序。基于该指标发现美国TAVR存在显著站点间质量差异,11%的站点表现低于预期。

要点

  • 复合指标纳入死亡率及卒中、出血、急性肾损伤、瓣周反流四种并发症。
  • 301个站点中8%表现优于预期,80%符合预期,11%低于预期。
  • 表现低于预期的站点各并发症发生率均显著更高。

核心结论

  • 美国TAVR医疗质量存在显著站点间差异,11%的站点表现低于全国平均水平。

研究设计与样本

  • 回顾性队列研究,使用STS/ACC TVT注册数据开发新型30天复合绩效排名指标。

主要发现

  • 基于与1年风险调整死亡率和健康状况的关联,确定纳入卒中和出血、急性肾损伤、瓣周反流四种并发症及死亡率。
  • 301个站点中25个(8%)表现优于预期,242个(80%)符合预期,34个(11%)表现低于预期。
  • 表现低于预期的站点30天死亡率、卒中、出血和瓣周漏均显著更常见。

关键数值与推荐

  • 复合指标并发症按与1年结局的调整关联确定入选和排序。
  • 站点风险调整结局基于95%概率区间显著高于或低于全国平均值分类为表现更差或更好。

临床怎么用

  • 该复合指标可用于TAVR站点绩效基准比较和质量改进。
  • 需进一步研究高表现和低表现站点相关的结构、流程和技术因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Transcatheter aortic valve replacement (TAVR) is a transformative therapy for aortic stenosis. Despite rapid improvements in technology and techniques, serious complications remain relatively common and are not well described by single outcome measures. The purpose of this study was to determine whether there is site-level variation in TAVR outcomes in the United States using a novel 30-day composite measure. METHODS: We performed a retrospective cohort study using data from the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapies Registry to develop a novel ranked composite performance measure that incorporates mortality and serious complications. The selection and rank order of the complications for the composite was determined by their adjusted association with 1-year outcomes. Sites with risk-adjusted outcomes significantly more or less frequent than the national average based on a 95% probability interval were classified as performing worse or better than expected. RESULTS: The development cohort consisted of 52 561 patients who underwent TAVR between January 1, 2015, and December 31, 2017. Based on associations with 1-year risk-adjusted mortality and health status, we identified 4 periprocedural complications to include in the composite risk model in addition to mortality. Ranked empirically according to severity, these included stroke, major, life-threatening or disabling bleeding, stage III acute kidney injury, and moderate or severe perivalvular regurgitation. Based on these ranked outcomes, we found that there was significant site-level variation in quality of care in TAVR in the United States. Overall, better than expected site performance was observed in 25/301 (8%) sites, performance as expected was observed in 242/301 sites (80%), and worse than expected performance was observed in 34/301 (11%) sites. Thirty-day mortality; stroke; major, life-threatening, or disabling bleeding; and moderate or severe perivalvular leak were each substantially more common in sites with worse than expected performance as compared with other sites. There was good aggregate reliability of the model. CONCLUSIONS: There are substantial variations in the quality of TAVR care received in the United States and 11% of sites were identified as providing care below the average level of performance. Further study is necessary to determine structural, process-related, and technical factors associated with high- and low-performing sites.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Desai ND, O'Brien SM, Cohen DJ, et al. Composite Metric for Benchmarking Site Performance in Transcatheter Aortic Valve Replacement: Results From the STS/ACC TVT Registry. Circulation. 2021. PMID: 33947202. doi:10.1161/CIRCULATIONAHA.120.051456

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。